Raymond James cut shares of Amneal Pharmaceuticals (NYSE:AMRX) from a strong-buy rating to an outperform rating in a research report sent to investors on Wednesday, The Fly reports. They currently have $8.50 price target on the stock, down from their prior price target of $13.00.

A number of other equities research analysts also recently issued reports on AMRX. SunTrust Banks began coverage on shares of Zoetis in a research note on Tuesday, March 19th. They issued a hold rating and a $100.00 price target on the stock. Barclays reissued a hold rating on shares of Bank of Montreal in a research note on Tuesday, June 11th. ValuEngine downgraded shares of Whiting USA Trust II from a hold rating to a sell rating in a research note on Tuesday, May 7th. Zacks Investment Research downgraded shares of Haynes International from a hold rating to a sell rating in a research note on Wednesday, May 8th. Finally, Piper Jaffray Companies set a $92.00 price target on shares of Wintrust Financial and gave the company a buy rating in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $14.58.

AMRX stock traded down $0.31 during trading on Wednesday, reaching $4.05. 4,424,718 shares of the stock were exchanged, compared to its average volume of 1,140,625. The company has a quick ratio of 1.37, a current ratio of 2.11 and a debt-to-equity ratio of 3.44. The stock has a 50 day simple moving average of $7.21. Amneal Pharmaceuticals has a 1 year low of $4.02 and a 1 year high of $24.48. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of 4.26, a price-to-earnings-growth ratio of 0.41 and a beta of 1.51.

Amneal Pharmaceuticals (NYSE:AMRX) last issued its earnings results on Thursday, May 9th. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.07). Amneal Pharmaceuticals had a positive return on equity of 32.14% and a negative net margin of 3.75%. The firm had revenue of $446.00 million for the quarter, compared to analysts’ expectations of $438.18 million. The firm’s revenue was up 4.9% compared to the same quarter last year. Sell-side analysts expect that Amneal Pharmaceuticals will post 0.91 EPS for the current fiscal year.

In other Amneal Pharmaceuticals news, SVP Joseph Todisco bought 15,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were purchased at an average cost of $9.88 per share, with a total value of $148,200.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Pradeep Bhadauria bought 7,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were acquired at an average cost of $8.48 per share, for a total transaction of $59,360.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 41,000 shares of company stock worth $387,300. 26.34% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in AMRX. Norges Bank purchased a new stake in Amneal Pharmaceuticals during the 4th quarter worth approximately $18,243,000. Marshall Wace LLP increased its stake in Amneal Pharmaceuticals by 487.8% during the 1st quarter. Marshall Wace LLP now owns 492,275 shares of the company’s stock worth $6,977,000 after buying an additional 408,533 shares during the period. Phocas Financial Corp. purchased a new stake in Amneal Pharmaceuticals during the 1st quarter worth approximately $5,331,000. Spark Investment Management LLC grew its holdings in Amneal Pharmaceuticals by 142.0% during the 1st quarter. Spark Investment Management LLC now owns 359,600 shares of the company’s stock worth $5,095,000 after acquiring an additional 211,000 shares in the last quarter. Finally, Stifel Financial Corp grew its holdings in Amneal Pharmaceuticals by 30.4% during the 4th quarter. Stifel Financial Corp now owns 578,967 shares of the company’s stock worth $7,807,000 after acquiring an additional 134,910 shares in the last quarter. 36.05% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

See Also: What is required to own or exchange cryptocurrency?

The Fly

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.